MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) was the recipient of a large decline in short interest in May. As of May 29th, there was short interest totaling 457,830 shares, a decline of 49.7% from the May 14th total of 910,289 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average daily volume of 718,711 shares, the short-interest ratio is presently 0.6 days.

MDxHealth Price Performance

NASDAQ:MDXH traded down $0.04 during mid-day trading on Friday, hitting $0.54. 584,274 shares of the company’s stock were exchanged, compared to its average volume of 881,817. MDxHealth has a one year low of $0.51 and a one year high of $5.33. The business has a fifty day moving average price of $1.49 and a 200 day moving average price of $2.74. The company has a market cap of $26.84 million, a PE ratio of -0.83 and a beta of 1.36.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%.The business had revenue of $23.90 million for the quarter, compared to the consensus estimate of $30.89 million. On average, equities analysts forecast that MDxHealth will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Several hedge funds have recently bought and sold shares of MDXH. GSA Capital Partners LLP bought a new stake in MDxHealth during the third quarter worth about $48,000. Jefferies Financial Group Inc. bought a new stake in MDxHealth during the third quarter worth about $53,000. Russell Investments Group Ltd. bought a new stake in MDxHealth during the third quarter worth about $461,000. Kennedy Capital Management LLC purchased a new position in MDxHealth in the third quarter worth about $1,826,000. Finally, FreeGulliver LLC raised its holdings in MDxHealth by 104.7% in the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock worth $1,176,000 after buying an additional 129,348 shares during the last quarter.

Wall Street Analyst Weigh In

MDXH has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research note on Friday, March 27th. William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. BTIG Research cut their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Wall Street Zen lowered shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Lake Street Capital cut their target price on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $4.63.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.